Smith Stan 4
4 · MAIA Biotechnology, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
MAIA Director Stan Smith Receives Stock Option Award
What Happened
- Stan Smith, a director of MAIA Biotechnology, was granted a derivative award on 2026-06-30: options covering 32,003 shares. The Form 4 reports an acquisition price of $0 and a total reported value of $0 for the award.
Key Details
- Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely).
- Transaction type: Award/Grant of stock options (derivative), reported as A.
- Shares involved: options for 32,003 shares.
- Reported price/value: $0.00 per share; total reported acquisition value $0.
- Vesting/exercise: Per footnote, the options vest 100% on the grant date and are exercisable immediately.
- Beneficial ownership: The securities are beneficially owned through "The Stan V. Smith Trust Dated 1993" (footnote).
- Exercise price or other economic terms beyond immediate vesting are not specified in the provided filing.
Context
- This filing reflects a stock option grant (an award), not an open-market purchase or sale. Although the reported acquisition value is $0, the grant gives the holder the right to buy shares under the option terms; any future exercise, sale, or tax-withholding actions would be reported separately.
Insider Transaction Report
Form 4
Smith Stan
Director
Transactions
- Award
Stock Options
[F1][F2]2026-06-30+32,003→ 32,003 total(indirect: See footnote)Exercise: $1.44From: 2026-06-30Exp: 2036-06-30→ Common Stock (32,003 underlying)
Footnotes (2)
- [F1]The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
- [F2]These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Signature
/s/ Stan V. Smith|2026-07-02